HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN

National Cancer Institute

Source

A recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2E6E7), with potential immunoprotective and antineoplastic properties. Upon administration, HPV16 L2E6E7 fusion protein vaccine TA-CIN may stimulate the immune system to generate HPV16 E6E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.